Bonness Enterprises Inc. trimmed its holdings in GlaxoSmithKline plc (NYSE:GSK) by 28.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,700 shares of the pharmaceutical company’s stock after selling 12,000 shares during the quarter. Bonness Enterprises Inc.’s holdings in GlaxoSmithKline were worth $1,053,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of the stock. Principal Financial Group Inc. bought a new stake in GlaxoSmithKline during the 2nd quarter valued at about $602,000. Eagle Asset Management Inc. increased its stake in GlaxoSmithKline by 10.9% during the 2nd quarter. Eagle Asset Management Inc. now owns 11,162 shares of the pharmaceutical company’s stock valued at $481,000 after purchasing an additional 1,094 shares in the last quarter. HPM Partners LLC increased its stake in GlaxoSmithKline by 1.2% during the 2nd quarter. HPM Partners LLC now owns 12,378 shares of the pharmaceutical company’s stock valued at $534,000 after purchasing an additional 144 shares in the last quarter. Coastline Trust Co bought a new stake in GlaxoSmithKline during the 2nd quarter valued at about $202,000. Finally, Summit Global Investments increased its stake in GlaxoSmithKline by 17.4% during the 2nd quarter. Summit Global Investments now owns 14,620 shares of the pharmaceutical company’s stock valued at $630,000 after purchasing an additional 2,170 shares in the last quarter. Institutional investors own 9.80% of the company’s stock.
In related news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of GlaxoSmithKline stock in a transaction dated Monday, November 6th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 10.00% of the company’s stock.
GlaxoSmithKline plc (GSK) traded up $0.42 during midday trading on Tuesday, reaching $37.92. 7,439,078 shares of the company’s stock were exchanged, compared to its average volume of 6,202,818. GlaxoSmithKline plc has a 12 month low of $34.52 and a 12 month high of $44.53. The company has a market cap of $93,530.00, a PE ratio of 28.95, a price-to-earnings-growth ratio of 2.15 and a beta of 0.97. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%. sell-side analysts predict that GlaxoSmithKline plc will post 2.9 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 11th. Stockholders of record on Friday, November 10th were given a dividend of $0.5037 per share. The ex-dividend date was Thursday, November 9th. This represents a $2.01 annualized dividend and a dividend yield of 5.31%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 155.73%.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.